SAN FRANCISCO—If there’s one silver lining to the COVID-19 pandemic, it’s the amount of rapid innovation that occurred across medtech, biotech and healthcare to better serve patients who had either ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Freenome said Friday it plans to go public in a deal that ...

(Reuters) - Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple ...

Verily, part of Google's parent company Alphabet, quietly invested in a life sciences start-up called Freenome and built it a lab to sweeten the deal. That company has now moved in to the lab on ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...

– Final module for the first version of Freenome's colorectal cancer test has been submitted to FDA; approval and commercial launch anticipated in 2026 – – Availability of real-world patient and ...

– Collaboration is designed to improve analytical speed and accuracy of Freenome's blood-based cancer screening tests – BRISBANE, Calif., Jan. 12, 2026 /PRNewswire/ -- Freenome today announced an ...

One of the major problems that technology companies working to find a cure for cancer need to solve is finding a safe, minimally invasive way to detect cancers early. Almost all cancer screening will ...

If liquid biopsies haven’t yet arrived, they’re definitely preparing the cabin for a timely descent. On Wednesday, San Francisco, California-based Freenome announced a $65 million Series A funding ...

Investors have poured boatloads of cash into liquid biopsy companies promising that their technology is the solution for non-invasive screening of early-stage cancer. In the latest mega funding round, ...

Freenome continues to draw strong financial support for its development work, with $270 million in new funds to push its cancer-detecting blood test through clinical trials and across the finish line ...